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Objectives: To investigate whether and by what 
means tourists travelling to holiday destinations in 
the tropics and subtropics seek to prepare their skin 
for the planned sun exposure,to examine their sun 
protective behavior,and to assess their sunburn rate 
during the vacation.
Methods: Between February and April 2013,we con-
ducted structured face-to-face interviews among 
passengers waiting in the departure or the baggage 
claim area at the Airport Basel-Mulhouse (Switzer-
land/France). Passengers of at least age 18 with 
Caucasian skin whose holiday destination was the 
Caribbean (Cancun, Punta Cana), the Canary Islands 
(Fuerteventura, Gran Canaria, Teneriffa) or North Af-
rica (Marrakech, Hurghada, Sharm el-Sheikh) were 
eligible for interviews.
Results: We completed 533 interviews with depart-
ing and 324 interviews with homecoming tourists.
Of the departing tourists, 10.1% visited a solarium 
within the 4 weeks preceding the vacation, 72.2% 
of them with the intent of preparing their skin for 
the anticipated sun exposure and thereby prevent-
ing sunburn. Furthermore, 7.8% sought to prepare 
the skin by taking dietary supplements such as ca-
rotenoids (however, 59.5% started the supplemen-
tation less than 9 weeks before departure and were 
thus unlikely to benefit from any extra protection). 
Almost all (97.4%) departing tourists had sunscreen 
in their luggage. The majority used sunscreen with 
a medium to very high sun protection factor (SPF 
15-20: 8.3%; SPF 25-30: 46.2%; SPF≥40: 41.2%). Yet, 
21.0% of sunscreen users stated to reduce the SPF 
on average by half after some days of sun exposure. 
Other sun protective items in the tourists’ luggage 
included sunglasses (93.8%), sunhat (63.6%), and 
clothes with integrated UV protection (4.1%).
Of the homecoming tourists, 79.0% nearly always 
applied sunscreen on sunny days, whereas only 
34.0% and 38.9% usually wore a sunhat and stayed 
in the shade around noon, respectively. Of concern, 
44.4% affirmed to have suffered from sunburn dur-
ing their vacation (nearly every third sunburn was 
described as painful). Male gender, younger age, 
not wearing a sunhat and only sometimes using 
sunscreen were associated with increased odds of 
sunburn.
Conclusion:The observed sunburn rate was alarm-
ingly high. Future skin cancer prevention programs 
should reveal common misconceptions in terms of 
preparing the skin for the sun and emphasize the 
avoidance of sunburns, the correct use of sunscreen 
as well as the importance of covering up and seek-
ing shade.
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In this study, we sought to investigate the antigen-
specificity and cytokine profile of human tissue-
homing and tissue-resident memory T helper cells.
Human skin-homing (CLA+) and gut-homing (al-
pha4beta7+) memory T helper cells isolated from 
PBMCs were stimulated with a broad panel of viral, 
bacterial, and fungal pathogens and proliferation 
and cytokine production was measured. Addition-
ally, tissue-resident T cells from skin and gut were 
isolated and analyzed for their cytokine profile.
In accordance with current concepts of tissue-spe-
cific imprinting of homing receptors in naive T cells 
in the course of infection, pathogen-specific T cells 
in PBMCs showed homing potential to the predomi-
nant site of infection of the respective pathogen. In-
triguingly, cytokine analysis revealed that IL-9 was 
exclusively produced by CLA+ T cells stimulated 
with Candida albicans but not by alpha4beta7 or 
CLA-/ alpha4beta7- T cells. No other pathogens elic-
ited significant production of IL-9 in any subpopula-
tion of T cells. Further investigation of the cytokine 
profile of skin-homing T helper cells showed that 
TGF-beta induces the expression of IL-9 but not IL-
4, IL-17, or interferon-gamma in CLA+ but not CLA- 
memory T cells. These IL-9 producing cells also lack 
the regulatory T cell maker FoxP3, thus showing the 
phenotype of bona fide Th9 cells. To assess whether 
the skin-homing Th9 cells found in the peripheral 
blood are indeed present in the skin, we analyzed 
the cytokine profile of tissue-resident T cells iso-
lated from healthy skin and gut using the explant 
culture technique. In accordance with our previous 
findings, skin-resident T cells contained a distinct 
population of Th9 cells whereas gut-resident T cells 
did not.
These results indicate that human Th9 cells distinct-
ly home to and reside in the skin and that they may 
show distinct antigenic specificity to the cutane-
ous pathogen C. albicans. Thus, our data establish 
a link between tissue-specific imprinting of homi 
ng potential and pathogen-specific imprinting of 
cytokine profiles during the course of T helper dif-
ferentiation.
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Objective: To characterize the blister cells isolated 
from an erythema exsudativum multiforme majus/
Stevens-Johnson Syndrome (EEMM/SJS) overlap 
and to investigate its cause.
Methods: The cutaneous eruption was classified ac-
cording to consensus definitions and histological 
analysis. Blister cells were analyzed for their expres-
sion of lineage and activation markers and cytotoxic P
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molecules using flow cytometry. T cell reactivity for 
potentially causative drugs was assessed by lym-
phocyte transformation tests (LTT).
Results: The healthy 58 year-old woman suffered 
from mild respiratory tract infection and therefore 
started treatment with the secretolytic drug Am-
broxol. One week later, she presented with large 
palmar and plantar blisters, painful mucosal ero-
sions, and flat atypical target lesions and maculae 
on the trunc, thus showing the clinical picture of an 
EEMM/SJS overlap. This diagnosis was supported by 
histology.
Analysis of blister ce lls showed that they mainly 
consisted of CD8+ and CD4+ T cells and a minor 
population of NK cells. Both the CD8+ T cells and 
the NK cells were highly activated and expressed 
Fas ligand and the cytotoxic molecule granulysin. In 
addition, both T cells and NK cells were positive for 
the chemokine receptor CCR4.
Surprisingly, the LTT performed on PBMCs in the 
acute phase was positive for Ambroxol (SI=2.9) 
whereas a LTT from a healthy but exposed individu-
al did not show unspecific proliferation. Laboratory 
tests for common infectious causes of EEMM were 
negative.
Conclusions: The highly activated CD8+ T cells and 
NK cells expressing FasL and granulysin in blister 
fluids of EEMM/SJS further support a key role of im-
mune cell-mediated cytotoxicity in blistering skin 
reactions. The upregulation of the skin-homing re-
ceptor CCR4 on NK cells from blister fluids indicates 
that cutaneous recruitment of NK cells may contrib-
ute to widespread keratinocyte death in these reac-
tions. Finally, the positive LTT for Ambroxol together 
with the medical history, negative test for common 
infectious causes and histology (eosinophils) indi-
cates that drug hypersensitivity to Ambroxol may 
have contributed to the EEMM/SJS in this patient. 
Further investigations of cutaneous adverse drug 
reactions to Ambroxol are thus warranted.
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 We report 2 patients with cold urticaria with differ-
ent response to treatment with omalizumab (Xo-
lair(®)). Cold contact urticaria (CCU) is a common 
subtype of physical urticaria. It is characterized by 
the development of wheal and/or angioedema 
within minutes after cold contact. Clinical manifes-
tation of CCU can range from mild, localized wheal-
ing to life-threatening anaphylactic shock reactions.
Omalizumab has been described to be useful in cas-
es of chronic urticaria (chronic spotaneous urticar-
ia) and may be an interesting option for treatment 
of CCU. We describe one patient with significant 
and long-lasting improvement of symptoms af-
ter300mg Omalizumab every 4 weeks for 3 months 
and one without any improvement after anti-immu-
noglobulin E therapy.
In our case reports, we want to highlight that there 
is still a small group of patients without benefit from 
omalizumab treatment. It is necessary to identify 
this minor subgroup of patients where omalizumab 
does not represent an effective treatment possibil-
ity. We also review the literature and compare with 
other cases of CCU treated with Omalizumab.
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We report the case of a 75-year-old man who suf-
fered from metastatic melanoma on his scalp, pT4b 
pN3 M1b. The patient received several excisions 
with a latissimus dorsi flap and a neck dissection 
of lymph nodes from level V. Two months later the 
PET-scan showed local progression of the tumor. 
Genetic testing confirmed a BRAF V600E mutation. 
We decided to include him into the GSK Combi-V 
trial (MEK116513) that investigated the combined 
therapy with dabrafenib, a selective BRAF inhibi-
tor, and trametinib, a selective MEK inhibitor. In the 
first week of therapy the patient responded well 
and showed clinical regression of the metastases. 
Nevertheless, one week later the metastases started 
to progress rapidly. CT scan confirmed the tumor 
spreading. As the response to immunotherapy is 
delayed we decided to treat the patient with che-
motherapy. The patient declined any systemic ther-
apy but wished only palliative care.
Targeted therapy with a BRAF kinase inhibitor in 
melanoma patients with a BRAF V600 mutation is 
known to develop resistance. To prevent this resis-
tance a phase I and II trial of combined treatment 
with dabrafenib and trametinib compared to mono-
therapy with dabrafenib has been conducted (fund-
ed by GlaxoSmithKlein). Flaherty et al. [1] showed 
that progression free survival was significantly im-
proved with the combined therapy (9.4 months ver-
sus 5.8 months). Also the rate of complete or partial 
response was significantly higher in the combina-
tion group (76% versus 54%). Furthermore the com-
bination of dabrafenib and trametinib showed less 
adverse events than the monotherpay with dab-
rafenib.
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